Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

(2009) L. Farina et al.   HAEMATOLOGICA

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

(2008) Julio Delgado et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning

(2008) Parameswaran Hari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

(2008) M. A. Phelps et al.   BLOOD

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

(2008) F. Bosch et al.   CLINICAL CANCER RESEARCH

Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis

(2008) Johannes Schetelig et al.   JOURNAL OF CLINICAL ONCOLOGY

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

(2008) Mohamed L. Sorror et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2008) Apostolia M. Tsimberidou et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

(2008) M Ritgen et al.   LEUKEMIA

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

(2008) J E Castro et al.   LEUKEMIA

Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years

(2008) Pankaj Malhotra et al.   LEUKEMIA & LYMPHOMA

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma

(2007) Andrew R. Rezvani et al.   JOURNAL OF CLINICAL ONCOLOGY